" class="no-js "lang="en-US"> Shabbir Mostafa, Recipharm, on Medical Devices
Monday, June 05, 2023

Breaking News

Providence Therapeutics Announces Partnership with University Health Network (UHN) for mRNA Therapeutic Discovery and Development Affini-T Therapeutics Appoints Industry Veteran Thaminda Ramanayake, M.S., MBA, as Chief Business Officer Feinstein Institutes Bioelectronic Medicine Researchers Stimulate Vagus Nerve to Reduce Bleeding in Hemophilia Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in Lupus Nephritis Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency CANbridge Announces Marketing Approval of CAN108 in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome GC Biopharma Receives a Business License for the Construction of a Plasma Fractionation Plant and Technology Transfer in Indonesia Cytovation Raises $8 Million in Series A Extension Financing Round for Clinical Advancement of CyPep-1, a First-in-class Targeted Tumor Membrane Immunotherapy FUJIFILM Cellular Dynamics Introduces First-of-its-Kind Human iPSC-derived Blood-Brain Barrier Isogenic Kit Landmark Bio Partners With InnDura Therapeutics to Advance Immune Cell Therapy Research

February 22 2023

Shabbir Mostafa, Recipharm, on Medical Devices

In this video, Shabbir Mostafa, the Head of Business Development at Recipharm, discusses Recipharm’s focus on contract development and manufacturing of medical devices. He explains that Recipharm offers a wide range of services, from product development to manufacturing, packaging, and distribution.

Mostafa also highlights some of Recipharm’s recent projects, including the development of a nasal device for administering rescue medicines, as well as the production of innovative inhalers. He is passionate about showcasing Recipharm’s innovative products, as well as showing clients the company’s service from development, right through to commercialisation.

  1. Providence Therapeutics Announces Partnership with University Health Network (UHN) for mRNA Therapeutic Discovery and Development

    News

     Read more
  2. Affini-T Therapeutics Appoints Industry Veteran Thaminda Ramanayake, M.S., MBA, as Chief Business Officer

    Appointments

     Read more
  3. Feinstein Institutes Bioelectronic Medicine Researchers Stimulate Vagus Nerve to Reduce Bleeding in Hemophilia

    Diseases

     Read more
  4. Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in Lupus Nephritis

    Drug Development

     Read more
  5. Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency

    Drug Development

     Read more
More On